US-based biopharmaceutical company Apollomics, Inc. on Monday announced that it has raised $100 million in a Series B financing round led by Hong Kong’s CMB International (CMBI), a subsidiary of China Merchants Bank.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
